Citius Pharmaceuticals to Present at the 9th Annual LD Micro Main Event

LOS ANGELES, CA / ACCESSWIRE / November 21, 2016 / Citius Pharmaceuticals, Inc. CTXR, a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical care drug products, announced today that it will be presenting at the 9th Annual LD Micro Main Event on Tuesday, December 6 at 9:30 AM PST / 12:30 PM EST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

During the conference, Chairman, Mr. Leonard Mazur will deliver the Company's corporate presentation and discuss recent business highlights. Management will also be available for one-on-one meetings. To arrange a meeting with management, please contact Mr. Andrew Scott: ascott@citiuspharma.com.

The LD Micro Main Event is the largest independent conference for small/microcap companies and will feature 240 presenting names.

View Citius Pharmaceuticals' profile here: http://www.ldmicro.com/profile/CTXR

News Compliments of Accesswire

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented, or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches (www.citiuspharma.com).

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and microcap universe.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com/events for more information.

Contact:
Andrew Scott
Vice President, Corporate Development
646-522-8410; ascott@citiuspharma.com

SOURCE: Citius Pharmaceuticals, Inc. via LD Micro